Pralatrexate: Phase I data

In an ongoing, open-label, dose-escalation Phase I trial in 31 patients, weekly Folotyn at doses <=15 mg/m 2 for 3 weeks of a 4-week cycle produced 2 complete responses and 9 partial responses. Data w...